Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses multidisciplinary care for genitourinary (GU) malignancies.

More and more patients with GU malignancies are being treated with multidisciplinary teams rather than solely urologists or medical oncologists.

Through this, many patients are receiving a treatment combination of cytotoxic chemotherapy and immunotherapy, Lallas says. He advises urologists that they must become familiar with the combination, as treatment is no longer just in the hands of the medical oncologist.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Immunotherapy in GU Cancers

The OncLive Immunotherapy in GU Cancers condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in genitourinary malignancies, specifically prostate cancer, urothelial carcinoma, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Sidney Kimmel Cancer Center at Jefferson

Cancer Centers

Partner

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses multidisciplinary care for genitourinary malignancies.
 

Dr. Lallas Discusses Multidisciplinary Care for Genitourinary Malignancies